AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Why AstraZeneca May Be 2025's Most Underrated Pharma Stock
In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective HER2-directed ADC, was $596 million in the first quarter of 2025, an increase of 29.3% year-over-year. Meanwhile, sales of Ultomiris, the flagship of AstraZeneca's Rare Disease segment and the successor of Soliris, reached $1.05 billion in the first three months of 2025, increasing by 22.2% year-on-year.
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AstraZeneca's Imfinzi delays bladder cancer return in high-risk patients
AstraZeneca PLC (LSE:AZN) has reported encouraging results from a late-stage trial of its cancer immunotherapy Imfinzi, which significantly extended the time patients with early-stage bladder cancer lived without their disease coming back or getting worse. The data, released Friday, come from the company's phase III POTOMAC trial and mark a potential breakthrough for patients with high-risk non-muscle-invasive bladder cancer, a form of the disease that accounts for the majority of bladder cancer diagnoses and has a stubborn tendency to return.
Tempus AI Stock: Time to Double Down or Cut and Run?
Tempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca NASDAQ: AZN, with advances in medicine impossible without computerized assistance.
AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) on the back of an appointment by Donald Trump and his health secretary Robert F Kennedy Jnr of a key position at the US drug regulator. Vinay Prasad, a vaccine sceptic like Kennedy, has been made head of the US Food and Drug Administration's Center for Biologics Evaluation and Research.
AZN or ARGX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
AstraZeneca has plenty coming down the pipeline to appease the bears
AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS believes underplays the company's longer-term potential. The bank retains its 'buy' rating with a price target of 14,200p, offering more than 30% upside from the current share price of around 10,600p.
AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript
AstraZeneca PLC (NASDAQ:AZN ) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ET Company Participants Andy Barnett - Head of IR Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - EVP, Oncology Business Unit Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Unit Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - CEO, Alexion Iskra Reic - EVP, International Conference Call Participants Sarita Kapila - Morgan Stanley James Gordon - JPMorgan Rajan Sharma - Goldman Sachs? Sachin Jain - Bank of America Steve Scala - Cowen Mattias Haggblom - Handelsbanken Matthew Weston - UBS Justin Smith - Bernstein Seamus Fernandez - Guggenheim Simon Baker - Redburn Rajesh Kumar - HSBC Luisa Hector - Berenberg Peter Verdult - BNP Operator Good morning to those joining from the UK and the U.S. Good afternoon to those in Central Europe and good evening to those listening in Asia.
AstraZeneca shares claw their way back into green after revenue miss
After an early stumble, AstraZeneca PLC (LSE:AZN) shares pulled back to level by the close on Tuesday, but analysts see reasons for investors to stay watchful despite the apparent strength of the results. At face value, the update looked reassuring.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
